Halaven (Eribulin)

Halaven (eribulin) is a prescription intravenous antineoplastic agent approved in the European Union for the treatment of certain advanced cancers. It belongs to the microtubule inhibitor class and works by disrupting microtubule dynamics, leading to cell‑cycle arrest and apoptosis of malignant cells. Halaven is administered by a healthcare professional as an IV infusion; specific strength and formulation details are defined by the marketing authorization in clinical practice.

Halaven is indicated for use in adult patients with specific metastatic solid tumours.

- Treatment of metastatic breast cancer that has progressed after prior chemotherapy regimens. - Therapy for unresectable or metastatic liposarcoma in patients who have received prior anthracycline‑containing therapy. - Use as a single‑agent option when other standard systemic therapies are not suitable. - Administration in a controlled clinical setting under oncologist supervision. - Consideration for use in combination with supportive care measures as directed by the treating physician.

The safety profile of Halaven includes a range of adverse events that vary in frequency and severity.

Common: - Fatigue - Neutropenia - Anemia - Peripheral neuropathy - Nausea - Decreased appetite

Serious: - Febrile neutropenia - Severe infection - Pulmonary toxicity (interstitial pneumonitis) - Cardiac dysfunction - Thrombocytopenia with bleeding risk

Before initiating Halaven, clinicians should evaluate several precautionary factors to minimise risk.

- Assess baseline blood counts and organ function (liver, kidney) prior to each cycle. - Monitor for signs of infection, especially in neutropenic patients. - Evaluate cardiac status, as eribulin may affect left ventricular function. - Use caution in patients with pre‑existing peripheral neuropathy. - Avoid use during pregnancy; discuss contraception with women of child‑bearing potential. - Adjust dose in patients with hepatic impairment according to prescribing information. - Provide patient education on recognizing fever or respiratory symptoms.

Halaven may interact with other medicines, influencing its efficacy or safety.

Avoid: - Concurrent use of strong CYP3A4 inducers (e.g., rifampin, carbamazepine) that may reduce eribulin exposure. - Live vaccines during treatment due to immunosuppression.

Use with caution: - Co‑administration of other myelosuppressive agents (e.g., cyclophosphamide, paclitaxel) may increase risk of cytopenias. - Antifungal azoles that inhibit CYP3A4, potentially raising eribulin levels. - Drugs that prolong QT interval; monitor cardiac rhythm. - Concomitant use of anticoagulants, as thrombocytopenia may enhance bleeding risk.